ZEAL Stock Overview
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 3/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Zealand Pharma A/S Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | kr.581.50 |
52 Week High | kr.749.00 |
52 Week Low | kr.212.20 |
Beta | 0.67 |
1 Month Change | -19.12% |
3 Month Change | 29.68% |
1 Year Change | 151.30% |
3 Year Change | 184.49% |
5 Year Change | 329.79% |
Change since IPO | 631.45% |
Recent News & Updates
Recent updates
Auditors Are Concerned About Zealand Pharma (CPH:ZEAL)
Mar 17Here's Why We're Watching Zealand Pharma's (CPH:ZEAL) Cash Burn Situation
Oct 03Downgrade: Here's How Analysts See Zealand Pharma A/S (CPH:ZEAL) Performing In The Near Term
Aug 14Some Zealand Pharma A/S (CPH:ZEAL) Analysts Just Made A Major Cut To Next Year's Estimates
Mar 14Is Zealand Pharma's (CPH:ZEAL) 113% Share Price Increase Well Justified?
Mar 11What You Need To Know About Zealand Pharma A/S' (CPH:ZEAL) Investor Composition
Jan 12Shareholder Returns
ZEAL | DK Biotechs | DK Market | |
---|---|---|---|
7D | -2.2% | -2.5% | -1.4% |
1Y | 151.3% | -15.7% | 21.5% |
Return vs Industry: ZEAL exceeded the Danish Biotechs industry which returned -15.7% over the past year.
Return vs Market: ZEAL exceeded the Danish Market which returned 21.5% over the past year.
Price Volatility
ZEAL volatility | |
---|---|
ZEAL Average Weekly Movement | 11.9% |
Biotechs Industry Average Movement | 7.5% |
Market Average Movement | 4.6% |
10% most volatile stocks in DK Market | 9.1% |
10% least volatile stocks in DK Market | 3.0% |
Stable Share Price: ZEAL's share price has been volatile over the past 3 months.
Volatility Over Time: ZEAL's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Danish stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1997 | 253 | Adam Steensberg | www.zealandpharma.com |
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.
Zealand Pharma A/S Fundamentals Summary
ZEAL fundamental statistics | |
---|---|
Market cap | kr.36.21b |
Earnings (TTM) | -kr.703.74m |
Revenue (TTM) | kr.342.79m |
105.6x
P/S Ratio-51.5x
P/E RatioIs ZEAL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ZEAL income statement (TTM) | |
---|---|
Revenue | kr.342.79m |
Cost of Revenue | kr.688.10m |
Gross Profit | -kr.345.31m |
Other Expenses | kr.358.43m |
Earnings | -kr.703.74m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 16, 2024
Earnings per share (EPS) | -11.30 |
Gross Margin | -100.74% |
Net Profit Margin | -205.30% |
Debt/Equity Ratio | 0% |
How did ZEAL perform over the long term?
See historical performance and comparison